Christopher Mills
Angel Investor @ Harwood Capital Management
London, United Kingdom
Christopher Mills is a post-ipo equity investor at Harwood Capital Management in London focused on Health Care and Biotechnology. Christopher founded Harwood Capital Management in 2011, a successor from our former parent company J O Hambro Capital Management, which he co-founded in 1993. He is chief executive and investment manager of North Atlantic Smaller Companies Investment Trust plc and chief investment officer of Harwood Capital LLP. He is a non-executive director ofseveral companies. Christopher was a director of Invesco MIM, where he was head of North American investments and venture capital, and of Samuel Montagu International.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Christopher Mills invests in
Stages Christopher Mills invests in
Countries Christopher Mills invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Biotechnology 1 (33%)
- Medical Device 1 (33%)
- Health Diagnostics 1 (33%)
- Artificial Intelligence 1 (33%)
Stage
- Post-IPO Equity 2 (67%)
- Post-IPO Debt 1 (33%)
Country
- United States 1 (33%)
- United Kingdom 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, and patient stratification for drugclinical trials.RenalytixAI’s technology platform will draw from distinct sources of patient data, including large electronic health records, predictive blood-based biomarkers, and other genomic information for analysis by learning computer algorithms. RenalytixAI intends to build a deep, unique pool of kidney disease-related data for different AI-enabled applications designed to improve predictive capability and clinical utility over time. | $21.2M / Post-IPO Debt / Mar 31, 2022 | ||
| RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, and patient stratification for drugclinical trials.RenalytixAI’s technology platform will draw from distinct sources of patient data, including large electronic health records, predictive blood-based biomarkers, and other genomic information for analysis by learning computer algorithms. RenalytixAI intends to build a deep, unique pool of kidney disease-related data for different AI-enabled applications designed to improve predictive capability and clinical utility over time. | $8.8M / Post-IPO Equity / Mar 31, 2022 | ||
| Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body’s own immune system poses a threat to a successful transplant or graft. Patients’ immune systems differ in how they respond to the presence of the transplanted organ,characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient’s immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects. | $7.9M / Post-IPO Equity |
About Harwood Capital Management
Harwood Capital Management generates investment returns for its investors. Their funds take an active interest in the running of the companies in which they are invested. They focus on investments in securities and equity-related instruments such as convertible bonds and warrants.
Harwood Capital Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Nicholas Mills
Director and Fund Manager
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Christopher Mills invest in?
Christopher Mills invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Post-IPO Equity and Post-IPO Debt stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Christopher Mills?
Public channels for Christopher Mills include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Christopher Mills last invest?
The most recent investment recorded for Christopher Mills closed in Mar 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
